Use of gestagens in combination with (6S)5-methyl tetrahydro folate for endometriosis therapy with simultaneous reduction of the side effects of therapy and reduction in the risk of congenital deformities for with the onset of pregnancy
OA: closed
Abstract
Use of gestagen in combination with (6S)-5-methyltetrahydrofolate for the production of a pharmaceutical preparation (I) for the therapy of endometriosis with simultaneous reduction of therapy side-effects, preferably negative effects on bone density or bone metabolism, osteoporosis risk, risk of congenital malformations and pregnancy complications in early stage of pregnancy, is claimed, where the daily dose of the gestagen corresponds to at least an ovulation inhibiting dose to maximally dual of the ovulation inhibiting dose. - ACTIVITY : Gynecological; Osteopathic. - MECHANISM OF ACTION : None given.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-07-06T06:10:23.601157+00:00